The Medical Letter on Drugs and Therapeutics
June 19, 2017
- Abaloparatide (Tymlos) for Postmenopausal Osteoporosis
- Ocrelizumab (Ocrevus) for MS
- Acetylcysteine (Cetylev) for Acetaminophen Overdose
- Obalon Balloon System - Another Gastric Balloon for Weight Loss
- Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
- Comparison Table: Drugs for Postmenopausal Osteoporosis (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Abaloparatide (Tymlos) for Postmenopausal Osteoporosis
June 19, 2017 (Issue: 1523)The FDA has approved abaloparatide (Tymlos – Radius Health), a synthetic analog of human parathyroid hormone related peptide, for treatment of postmenopausal women with osteoporosis who are at high risk for fracture. Abaloparatide is...more
- Drugs for postmenopausal osteoporosis. Med Lett Drugs Ther 2014; 56:91.
- BZ Leder et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2015; 100:697.
- S Gonnelli and C Caffarelli. Abaloparatide. Clin Cases Miner Bone Metab 2016; 13:106.
- PD Miller et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016; 316:722.
- F Cosman et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc 2017; 92:200.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.